BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 10698497)

  • 1. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
    Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
    Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
    Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
    Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma.
    Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Oomen MH; Noordzij MA; Van den Heuvel MM; Nassef SM; Nijman RM; Van Steenbrugge GJ
    Clin Cancer Res; 2000 Nov; 6(11):4265-71. PubMed ID: 11106242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional properties of WT1.
    Haber DA; Englert C; Maheswaran S
    Med Pediatr Oncol; 1996 Nov; 27(5):453-5. PubMed ID: 8827073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
    Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
    Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wilms tumor and the WT1 gene.
    Lee SB; Haber DA
    Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of v-sis-dependent transformation by the transcription factor, Egr-1.
    Huang RP; Darland T; Okamura D; Mercola D; Adamson ED
    Oncogene; 1994 May; 9(5):1367-77. PubMed ID: 8152797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
    McCoy C; McGee SB; Cornwell MM
    Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus.
    Morris JF; Madden SL; Tournay OE; Cook DM; Sukhatme VP; Rauscher FJ
    Oncogene; 1991 Dec; 6(12):2339-48. PubMed ID: 1662794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function.
    Hewitt SM; Saunders GF
    Anticancer Res; 1996; 16(2):621-6. PubMed ID: 8687106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors.
    Iben S; Royer-Pokora B
    Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WT1 expression alters tumorigenicity of the G401 kidney-derived cell line.
    McMaster ML; Gessler M; Stanbridge EJ; Weissman BE
    Cell Growth Differ; 1995 Dec; 6(12):1609-17. PubMed ID: 9019166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Wilms' tumor genes.
    Hirose M
    J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
    Zhang X; Xing G; Saunders GF
    Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of the Wilms' tumor gene, WT1, during differentiation of embryonal carcinoma and embryonic stem cells.
    Scharnhorst V; Kranenburg O; van der Eb AJ; Jochemsen AG
    Cell Growth Differ; 1997 Feb; 8(2):133-43. PubMed ID: 9040935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells.
    Nichols KE; Re GG; Yan YX; Garvin AJ; Haber DA
    Cancer Res; 1995 Oct; 55(20):4540-3. PubMed ID: 7553624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imbalanced expression of functionally different WT1 isoforms may contribute to sporadic unilateral Wilms' tumor.
    Liu JJ; Wang ZY; Deuel TF; Xu YH
    Biochem Biophys Res Commun; 1999 Jan; 254(1):197-9. PubMed ID: 9920757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors.
    Liu J; Nau MM; Yeh JC; Allegra CJ; Chu E; Wright JJ
    Clin Cancer Res; 2000 Sep; 6(9):3522-9. PubMed ID: 10999739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
    Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
    Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.